Active, not recruitingPhase 2NCT05833438
Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
Studying Inherited acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Leipzig
- Principal Investigator
- Klaus Metzeler, Prof. Dr.Universitätsklinikum Leipzig, Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
- Intervention
- VEN+AZA-5(drug)
- Enrollment
- 45 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (10)
- Helios Klinikum Berlin-Buch Klinik für Hämatologie und Stammzelltransplantation, Berlin, Germany
- Klinikum Chemnitz gGmbH Klinik für lnnere Medizin Ill, Chemnitz, Germany
- Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus, Germany
- Universitatsklinikum Carl Gustav Carus Dresden an der TU Dresden Medizinische Klinik und Poliklinik 1 Bereich Hamatologie, Dresden, Germany
- Universitätsklinikum Heidelberg, Innere Medizin V; Klinik für Hämatologie, Onkologie und Rheumatologie, Heidelberg, Germany
- Universitätsklinikum Leipzig, Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie, Leipzig, Germany
- Kliniken Maria Hilf GmbH, Klinik für Hämatologie, Onkologie und Gastroenterologie, Mönchengladbach, Germany
- Rotkreuzklinikum München, III. Medizinische Abteilung, München, Germany
- Klinikum rechts der lsar der TU München, Klinik und Poliklinik für lnnere Medizin Ill, München, Germany
- Kliniken Sindelfingen,Medizinische Klinik I, Sindelfingen, Germany
Collaborators
AbbVie · University Hospital Leipzig, Hematology Diagnostics Laboratory · University of Leipzig, Clinical Trial Centre (ZKS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05833438 on ClinicalTrials.govOther trials for Inherited acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06782542Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyJustin Watts, MD
- RECRUITINGPHASE2NCT06557421De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07130695Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and ConsolidationVirginia Commonwealth University
- RECRUITINGPHASE1NCT07320235Imetelstat Combinations in Relapsed AMLDouglas Tremblay
- RECRUITINGPHASE2NCT06904482Co-Transplant of an Unmodified Haplo-Identical Graft With Cord BloodCase Comprehensive Cancer Center
- RECRUITINGNCT07163728Leptin: A Marker for AML Chemo-SensitivityFujian Medical University Union Hospital
- RECRUITINGNANCT06697600A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their CaregiversUniversity of Rochester
- RECRUITINGPHASE2, PHASE3NCT06972641Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRuijin Hospital